Overview

A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)

Status:
Active, not recruiting

Trial end date:
2022-12-29

Target enrollment:

Participant gender:

Summary

This is a study in participants with Exocrine Pancreatic Insufficiency (EPI) due to pancreatic cancer that has been resected. This study will include resected participants who are post pancreatic cancer surgery, and an additional cohort in non-resected participants.

Phase:

Phase 4

Details

Lead Sponsor:

AbbVie

Treatments:

Pancreatin
Pancrelipase